Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of the multi-targeted
protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as
a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.